21/11/2023 - 15:10

Tax rebate to help Radiopharm diagnose, treat cancers

21/11/2023 - 15:10


Upgrade your subscription to use this feature.

A research and development tax rebate of nearly $5 million from the Australian Government will boost Radiopharm Theranostics’ mission to further develop its suite of diagnostic and therapeutic products aimed at beating the cancer scourge. The refund recognises the company’s R&D activity during the 2023 financial year and comes as it prepares to run clinical pancreatic cancer trials in New York.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options